News & Events about Athira Pharma Inc.
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimers disease is progressing with targeted enrollment ...
Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal modelsBOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused ...
Shares of Athira Pharma, Inc. (NASDAQ:ATHA Get Rating) have been given a consensus recommendation of Moderate Buy by the six analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned...
PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Athira Pharma, Inc. (Athira or the Company) (NASDAQ: ATHA) on behalf of the Companys long-term investors. The investigation seeks to determine whether the members of Athiras board of directors violated...
Globe Newswire
2 months ago
Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) significantly correlated with improvements in clinical outcomes as assessed by the GST, a composite score of cognition (ADAS-Cog11) and function (ADCS-ADL23) Data demonstrate fosgonimeton ...